IP Verse

Methods Of Treatment Of Ocular Conditions With A Sustained Drug Delivery Implant - EP3068403

The patent EP3068403 was granted to Allergan on Jun 17, 2020. The application was originally filed on Nov 14, 2014 under application number EP14805768A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3068403

ALLERGAN
Application Number
EP14805768A
Filing Date
Nov 14, 2014
Status
Granted And Under Opposition
May 15, 2020
Publication Date
Jun 17, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DF MP DORRIES FRANK MOLNIA & POHLMAN PATENTANWALTE RECHTSANWALTE PARG MBBMar 16, 2021GREINERADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS7767223
DESCRIPTIONUS8034370
DESCRIPTIONUS8242099
DESCRIPTIONUS8257730
INTERNATIONAL-SEARCH-REPORTUS2005244469
INTERNATIONAL-SEARCH-REPORTUS8034366
OPPOSITIONUS8034370

Non-Patent Literature (NPL) Citations (10) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- EMA, "Assessment report for Ozurdex", Assessment Report EMA/439447/2011, (20110519), pages 1 - 44, URL: https://www.ema.europa.eu/en/documents/variation-report/ozurdex-h-c-1140-ii-0001-epar-assessment-report-variation_en.pdf, XP055795733
OPPOSITION- EMA, "Ozurdex", CHMP Assessment report - EMA/457364/2010, (20100000), pages 1 - 58, URL: https://www.ema.europa.eu/en/documents/assessment-report/ozurdex-epar-public-assessment-report_en.pdf, XP055795726
OPPOSITION- "History of Changes for Study: NCT00168337", (20130530), URL: https://clinicaltrials.gov/ct2/history/NCT00168337?V_13=View#StudyPageTop, XP055795698
OPPOSITION- "History of Changes for Study: NCT00168389", (20130621), URL: https://clinicaltrials.gov/ct2/history/NCT00168389?V_13=View#StudyPageTop, XP055795702
OPPOSITION- SCHWARTZ et al., "Intravitreal Corticosteroids in the Management of Diabetic Macular Edema", Curr Ophthalmol Rep, (20130726), vol. 1, pages 144 - 149, XP055795723
OPPOSITION- HALLER et al., "028397162 Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion", Ophthalmology, (20110000), vol. 118, pages 2453 - 2460, XP028397162
OPPOSITION- CALLANAN et al., "055795712 Dexamethasone Intravitreal Implant in Combination with Laser Photocoagulation for the Treatment of Diffuse Diabetic Macular Edema", Ophthalmology, (20130500), vol. 120, pages 1843 - 1851, XP055795712
OPPOSITION- BOYER et al., "Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema", Ophthalmology, (20140604), vol. 121, pages 1904 - 1914, XP055162551
OPPOSITION- PACELLA et al., "Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema", Clinical Ophthalmology, (20130716), vol. 7, pages 1423 - 1428, XP055162494
OPPOSITION- SALMAN, A.G., "Long-term effect of intravitreal dexamethasone implant (Ozurdex) in the treatment of resistant diabetic macular edema", Journal of Egyptian Ophthalmological Society, (20130000), vol. 106, no. 3, pages 194 - 198, XP055795706

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents